Anybody looking to profit from Big Pharma's next 1984 style planned-demic shake down of humanity ought to give GSK a look.
In a report published Monday, Bloomberg pointed to the efforts of GlaxoSmithKline, which is investing in its vaccine business in order to get ahead of the next pandemic, while continuing to develop the next generation of COVID-19 vaccines (since its international production capabilities could give it a leg up in catering to the developing world).
It's just the latest indication that President Biden's support for a WTO proposal to waive IP protections for COVID vaccines is mostly lip service, and that the pharmaceutical industry will do everything in its (considerable) power to stop it.
What's more, GSK is in talks with the British government to onshore more of its vaccine development and research capabilities, alongside production, according to the company's vaccines chief, Roger Connor. These labs will be equipped with "vaccine technologies to tackle deadly viruses of the future, he said in an interview." Presently, Glaxo’s main R&D vaccine hubs are based in Belgium, Italy and the US.
"When every government does their after-action review from this pandemic, they’ll start to think about manufacturing within their own boundary, or within their own region at least," said Connor. We want to "create in-country manufacturing and vaccine development capability for the future."
GSK and its hedge fund backers, which include Paul Singer's Elliott Management, are in the process of spinning off the company's consumer health division next year and leaving its biopharma and vaccine arms, businesses that Connor describes as the company's "crown jewels."
Whether the next pandemic is bird flu, or ebola, Connor ays GSK will be prepared: "We’ve got one of the widest range of technology platforms of any vaccine company," he said. To prepare for a future pandemic, "you need to have fill-finish, you need to have bulk, you need to have technology choice, you need to have an R&D engine that connects very well to academia, to government monitoring of virus evolution, and GSK brings all of those things."
Of course, the best-case scenario for GSK would be that it's present COVID jab trials lead to approval by year's end, leaving it plenty of time to tap into the massive international market for the next generation of vaccines, would require a proposal to waive IP for vaccines to fail.
GSK and its partner Sanofi plan to start advanced trials with more than 37,000 people in coming weeks, with multiple formulations of the vaccine to better protect against variants such as those first found in South Africa and India. The studies will predominantly be outside the U.S. and focused on geographies with higher infection rates to give “every chance of making the trial successful,” Connor said.
"Yes, there are others making more from Covid in the short term,” said Connor. "However, when we look at the overall portfolio, innovation and current assets that we have, we think it’s stronger than anyone’s and slightly under-appreciated at the moment."
Even before COVID, the company's vaccine revenues were rising, having climbed 50% in a four-year period. Shingles vaccine Shingrix is one of the company’s biggest products and Connor says there are other blockbusters in the pipeline, including its Respiratory Syncytial Virus shots for older adults and pregnant mothers, both in advanced trials.
To sum up: anybody looking to invest in a company that's well-positioned to combat the next Big Pharma 1984 style planned-demic shakedown ought to give GSK a look.
No comments:
Post a Comment